NEWSROOM
News Releases
The latest news about Samsung Bioepis
Samsung Life Science Fund Invests in Phrontline Biopharma to Advance Antibody-Drug Conjugate Therapeutics in Oncology
• An equity investment to support Phrontline’s development in innovative bispecific dual payload targeting a wide range of solid tumors including lung cancer, head and neck cancer, ovarian cancer and, renal cell carcinoma
INCHEON, Korea – November 25, 2025 – Samsung Life Science Fund, created jointly between Samsung C&T (KRX: 028260.KS), Samsung Biologics (KRX: 207940.KS), and Samsung Bioepis and managed by Samsung Ventures, today announced an equity investment in Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of antibody-drug conjugates (ADCs).
Phrontline Biopharma is a company specializing in the development of innovative ADCs through its proprietary bispecific antibody and dual-linker payload platforms that enhance payload delivery efficiency and enable the simultaneous delivery of two payloads with balanced potency and complementary mechanisms of action through a branched-linker architecture. Through its technology, the company aims to overcome the limitations of single-payload, single-target ADCs, particularly in addressing resistance, tumor heterogeneity, and durability of response in treating a wide range of solid tumors.
“ADCs are reshaping the future of cancer treatments, and Phrontline Biopharma has demonstrated compelling scientific and development capabilities,” said Minjeong Seo, Vice President and Leader of Exploration Team at Samsung Bioepis. “Through this investment, Samsung Life Science Fund aims to help accelerate the development of these ADC candidates into viable therapeutic options for oncology patients with unmet medical needs.”
Samsung Life Science Fund has been actively investing in biotechnology, and this investment further extends its commitment to advancing ADC technologies following earlier investments in Araris Biotech and Aimed Bio. With this addition, the Fund continues to diversify its portfolio and strengthen its focus on next-generation therapeutic modalities. Samsung Life Science Fund remains committed to advancing innovative treatments that address unmet medical needs and delivering meaningful impact for patients worldwide.
About Samsung Ventures
Samsung Venture Investment Corporation was established to promote promising small and medium-sized companies engaging in the development of new technologies. Our collaboration is based on managerial know-how and trust, and actively investing in future-oriented businesses based on new and innovative technologies that are expected to serve as new growth engines. Please visit our website for more detail: https://www.samsungventure.co.kr/english_main.do.
Media Contact – Samsung Bioepis
Media Contact – Samsung Bioepis
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com
